Seven Key Products Are Projected to Generate $1 Billion in Sales in 5 Years
LAVAL, Quebec, Jan. 9, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX andTSX: VRX) ("Valeant" or the "Company") announced today it has published the presentation that Joseph C. Papa, chairman and chief executive officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, tomorrow, Wednesday, Jan. 10, 2018, at 10:30 a.m. PST (1:30 p.m. EST).
The presentation provides an overview of the Company's recent performance and accomplishments in its transformation and offers insight into future catalysts, including seven key products that have been recently approved or are filed with the U.S. Food and Drug Administration. We believe these products will generate approximately $1 billion in expected annualized revenues at peak sales over the next five years.
The presentation is available on the Investor Relations page of the Valeant web site at: http://ir.valeant.com/events-and-presentations/2018.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
This news release may contain forward-looking statements which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
SOURCE Valeant Pharmaceuticals International, Inc.